期刊文献+

肾癌细胞和G250单克隆抗体复合物致敏树突状细胞肿瘤疫苗的制备

Preparation of dendritic cell-based cancer vaccines pulsed with G250 monoclonal antibody IgG-complexed renal carcinoma cells
下载PDF
导出
摘要 目的:以肾癌细胞和G250单克隆抗体(G250 monoclonal antibody,G250 mAb)复合物致敏树突状细胞(dendriticcells,DC)制备肾癌DC疫苗,并检测其活化水平,为临床应用DC肿瘤疫苗提供依据。方法:制备凋亡的肾癌细胞与G250mAb形成的复合物(G250 mAb IgG-complexed apoptotic tumor cell,IC-ATC)。取健康人新鲜外周血分离单个核细胞(peripheralblood mononuclear cell,PBMC),以GM-CSF和IL-4诱导PBMC成未成熟的树突状细胞(immature dendritic cells,iDC),将iDC分别负载凋亡肿瘤细胞(apoptotic tumor cell,ATC)、IC-ATC、G250 mAb,并均以TNF-α诱导成熟树突状细胞(mature dendriticcells,mDC),将未负载的DC作为对照组。流式细胞术检测各组mDC的免疫表型、ELISA试剂盒检测IL-12分泌水平,CCK-8法检测mDC刺激淋巴细胞增殖的能力。结果:成功制备IC-ATC致敏的DC疫苗。相对于负载ATC、G250mAb和未负载的DC,负载IC-ATC的DC疫苗显著上调CD86、CD80、CD83、HLA-DR的表达[(42.04±3.42)%vs(28.34±1.16)%、(33.77±1.61)%、(26.52±2.14)%,P<0.05;(38.17±2.55)%vs(23.79±2.41)%、(31.94±3.29)%、(24.32±3.23)%,P<0.05;(79.39±1.44)%vs(69.06±2.01)%、(74.49±1.35)%、(66.71±3.83)%,P<0.05;(35.52±2.72)%vs(26.90±2.82)%、(29.45±1.58)%、(27.42±2.11)%,P<0.05]和IL-12分泌水平(25.04 vs 5.27、13.32、7.53,P<0.05),且能更有效地刺激淋巴细胞增殖(4.02 vs 1.73、1.22、1.41,P<0.01)。结论:IC-ATC可有效促进DC成熟和活化,IC-ATC致敏的DC疫苗诱导淋巴细胞增殖能力显著增强。 Objective: To use G250 monoclonal antibody(G250 mAb) IgG-complexed renal carcinoma cells to acti-vate dendritic cells(DCs),develop the DC vaccine of renal carcinoma and determine its activation for clinical tumor biological therapy.Methods: Prepare apoptotic renal carcinoma cells and induce the G250 mAb-complexed apoptotic renal carcinoma cells(IC-ATC).Immature dendritic cells(iDCs) induced from peripheral blood mononuclear cells of healthy volunteers were cultured and propagated in vitro using rhGM-CSF and rhIL-4.iDCs were loaded with apoptotic renal carcinoma cells(ATC),IC-ATC and G250 mAb.Then mature dendritic cells(mDCs) were induced by TNF-α,while the DCs pulsed with no antigen served as a control group.The immune phenotype of mDCs in different groups was detected by flow cytometry,secretion of IL-12 by DCs was measured by ELISA and the ability of DCs to stimulate lymphocyte proliferation was examined by CCK-8 assay.Results: It was found that when compared with ATC,G250 mAb and the control group,the mDCs pulsed with IC-ATC obriously up-regulated the expressions of CD83,CD80,CD86,and HLA-DR([42.04±3.42]% vs [28.34±1.16]%,[33.77±1.61]%,[26.52±2.14]%,P0.05;[38.17±2.55]% vs [23.79±2.41]%,[31.94±3.29]%,[24.32±3.23]%,P0.05;[79.39±1.44]% vs [69.06±2.01]%,[74.49±1.35]%,[66.71±3.83]%,P0.05;[35.52±2.72]% vs [26.90±2.82]%,[29.45±1.58]%,[27.42±2.11]%,P0.05),and secreted higher quantity of IL-12(25.04 vs 5.27,13.32,7.53,P0.05).Moreover,mDCs loaded by IC-ATC induced multiplication of lymphocytes was more effective(4.02 vs 1.73,1.22 vs 1.41,P0.05).Conclusion: IC-ATC can promote DCs mature effectively,and DCs pulsed with IC-ATC can induce the proliferation and activation significantly.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2012年第1期40-44,共5页 Chinese Journal of Cancer Biotherapy
基金 辽宁省医学高峰建设工程专项基金(No.2010017)~~
关键词 树突状细胞 G250单克隆抗体 肾癌 肿瘤疫苗 dendritic cell G250 monoclonal antibody(G250 mAb) renal carcinoma cancer vaccine
  • 相关文献

参考文献17

  • 1Krutzik SR,Tan B,Li H,et al.TLR activation triggers the rapiddifferentiation of monocytes into macrophages and dendritic cells[J].Nat Med,2005,11(6):653-660.
  • 2Reinhard G,Marten A,Kiske SM,et al.Generation of dendriticcell-based vaccines for cancer therapy[J].Br J Cancer,2002,86(10):1529-1533.
  • 3张亚东,李晓飞.肾癌G250MN/CAIX抗原的研究进展[J].国外医学(泌尿系统分册),2005,25(1):12-16. 被引量:3
  • 4吴国英,李黔生,聂志林,李彦锋,靳风烁.5-氟尿嘧啶诱导肾癌细胞凋亡对Fas/FasL途径依赖性的研究[J].第三军医大学学报,2009,31(13):1254-1257. 被引量:6
  • 5Akiyama K,Ebihara S,Yada A,et al.Targeting apoptotic tumorcells to FcγR provides efficient and versatile vaccination againsttumors by dendritic cells[J].J Immunol,2003,170(4):1641-1648.
  • 6Dubois B,Lamy PJ,Chemin K,et al.Measles virus exploits den-dritic cells to suppress CD4+T-cell proliferation via expression ofsurface viral lycoproteins independently of T-cell trans-infection[J].Cell Immunol,2001,214(2):173-183.
  • 7原津津,潘晨.免疫复合物与树突状细胞[J].福建医药杂志,2007,29(5):114-116. 被引量:3
  • 8Mehta RC,Pike GB,Enzmann DR.Magnetization transfer MR ofin cancer development and progression[J].Int J Biol Markers,1998,13(2):51-69.
  • 9Pan CC,Chen PC,Tsay SH,et al.Differential immunoprofiles ofhepatocellular carcinoma,renal cell carcinoma,and adrenocoryicalcarcinoma:A systemic immunohistochemical survey using tissuearray technique[J].Appl Immunohistochem Mol Morphol,2005,13(4):347-352.
  • 10Yamagata M,Hasuda K,Stamato T,et al.The contribution of lac-tic acid to acidification of tumours:Studies of variant cells lackinglactate dehydrogenase[J].British J Cancer,1998,77(11):1726-1731.

二级参考文献82

  • 1任淑萍,包木胜,高新,于永利,王丽颖.HSP65-MUC1/HSP65抗体免疫复合物对人树突状细胞的活化作用[J].吉林大学学报(医学版),2005,31(2):182-185. 被引量:6
  • 2祝瑾,贾筱琴,程宏.5-FU诱导白血病细胞凋亡的分子机制研究[J].中华肿瘤防治杂志,2006,13(8):586-588. 被引量:6
  • 3Lehnert M. Multidrug resistance in human cancer[ J]. J Neurooncol, 1994, 22 (3) :239 - 243.
  • 4Debatin K M, Krammer P H. Death receptors in the chemotherapy and cancer[ J]. Oncogene, 2004, 23 (16) : 2950 - 2966.
  • 5Landman J, Olweny E, Sundaram C P, et al. Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma[ J]. J Urol, 2004, 171 (4) : 1456 - 1460.
  • 6Yoshida Y, Goto K, Kawahara K, et al. A phase I study of continuous administration of 5-fluorouracil/cisplatin in advanced uterine cervical cancer[J]. Anticancer Res, 2003, 22(6B):3473-3476.
  • 7Werner M, Eger K, Jurgen-Steinfelder H. Comparison of the rapid proapoptotic effect of trans-beta-nitrostyrencs with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells [ J ]. Apoptosis, 2007, 12 ( 1 ) :235 - 246.
  • 8Correale P, Cusi M G, Del-Vecchio M T, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic muhidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro[ J]. J Immunol, 2005, 175(2) :820 -828.
  • 9Nakamura M, Nagano H, Sakon M, et al. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro [ J ]. J Hepatol, 2007, 46 ( 1 ) : 77 - 78.
  • 10Potter CPS,Harris AL.Diagnostic,prognostic and therapeutic implications on carbonic anhydrases in cancer.Bri J Cancer,2003,89(1):2-7.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部